Breast Cancer Drug Trastuzumab (Herceptin) Shows Unprecedented Survival In Aggressive Stomach Cancer
Data from the ToGA study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida showed that adding trastuzumab to standard chemotherapy (capecitabine [Xeloda®] or intravenous 5-FU and cisplatin) prolongs the lives of patients with this aggressive cancer on average by nearly 2.7 months to 13.8 months, a 26% increase in survival. Advanced gastric (stomach) cancer is associated with a poor prognosis; the median survival time after diagnosis is approximately 10 months with currently available therapies.[i]
Public Health